ロード中...
Profile of pacritinib and its potential in the treatment of hematologic disorders
Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of Janus kinase 2 and FMS-related tyrosine kinase 3 providing potential in the treatment of hematological malignancies such as myeloproliferative neoplasias, acute myeloid leukemia, and various lymphomas. Pacritinib has po...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4145824/ https://ncbi.nlm.nih.gov/pubmed/25170285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S51253 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|